The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas
- 27 March 2019
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (6) , 658-666
Abstract
Indolent B‐cell lymphomas other than follicular lymphoma account for up to 10% of all B‐cell neoplasms. While they typically follow a slowly progressive course, some patients experience rapid progression and early mortality. Prognostic scoring systems have not been adopted, hindering the ability of clinicians or researchers to predict outcomes, or risk‐stratify patients during clinical trials. To address this, we evaluated the utility of existing prognostic indices and novel, early disease‐related outcomes, to predict subsequent long term survival. Baseline characteristics and outcomes data were generated from a longitudinal cohort study that prospectively enrolled 632 patients newly diagnosed with marginal zone lymphoma, lymphoplasmacytic lymphomas, or B‐cell lymphomas not otherwise specified, beginning in 2002. The International Prognostic Index (IPI), Follicular Lymphoma International Prognostic Index (FLIPI), and MALT International prognostic index (MALT‐IPI) demonstrated c‐statistics that ranged from 0.593‐0.612 for event‐free survival (EFS), and 0.683‐0.714 for overall survival (OS). Patients who attained event‐free survival at 12 months (EFS12) experienced similar mortality to the US general population (standardized mortality ratio [SMR] 1.19; 95% CI 0.95‐1.46). Patients who did not attain EFS12 had subsequent worse morality (SMR 3.14 (95% CI 2.05‐4.59). The MALT‐IPI demonstrated utility in predicting subsequent long‐term outcomes among patients with non‐follicular indolent B‐cell lymphomas. This index should be used by clinicians giving guidance to patients at the time of initial diagnosis, and risk stratification during clinical studies. The divergent long‐term outcomes experienced by patients who do or do not attain EFS12 suggest there exists a subset of patients who harbor high‐risk disease. Future research efforts should focus on methods to identify these patients at the time of diagnosis, in order to enable risk‐tailored therapy.Keywords
Funding Information
- National Institutes of Health (P50 CA CA97274)
This publication has 35 references indexed in Scilit:
- Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphomaBritish Journal of Haematology, 2012
- Marginal Zone Lymphomas With Plasmacytic Differentiation and Related DisordersAmerican Journal of Clinical Pathology, 2011
- Lymphoplasmacytic Lymphoma and Other Non–Marginal Zone Lymphomas With Plasmacytic DifferentiationAmerican Journal of Clinical Pathology, 2011
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood, 2008
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Background mortality in clinical survival studiesThe Lancet, 1993
- Multiplicative Models and Cohort AnalysisJournal of the American Statistical Association, 1983